Scholar Rock Holding (SRRK) closed at $43.21 on November 13, 2026, up 0.1% from the previous close, on volume of 582,141 shares (30-day average 1,681,869).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Seagull Ratio With Put Spread | 20-Nov-2640 P : 45[3x] P : 55[4x] C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Scholar Rock Earnings Call Highlights ISEMBYLD Launch Momentum
TipRanks (Sat, 14-Nov 8:12 PM ET)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Nov 4:15 PM ET)
Analysts Offer Insights on NA Companies: Scholar Rock Holding (SRRK) and Builders Firstsource (BLDR)
TipRanks (Thu, 12-Nov 3:20 AM ET)
Scholar Rock Holding (SRRK) Receives a Buy from Evercore ISI
TipRanks (Wed, 11-Nov 10:05 AM ET)
Scholar Rock Holding (SRRK) Gets a Buy from Piper Sandler
TipRanks (Wed, 11-Nov 8:45 AM ET)
Scholar Rock Holding (SRRK) Receives a Buy from Canaccord Genuity
TipRanks (Wed, 11-Nov 8:36 AM ET)
Isembyld Launch Indicators Support Buy Rating; $74 Price Target Unchanged
TipRanks (Wed, 11-Nov 5:35 AM ET)
Barclays Keeps Their Hold Rating on Scholar Rock Holding (SRRK)
TipRanks (Wed, 11-Nov 4:05 AM ET)
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Scholar Rock Holding (SRRK)
TipRanks (Tue, 10-Nov 4:20 PM ET)
BioNTech to buy Scholar Rock Priority Review Voucher for $205M
Seeking Alpha News (Tue, 10-Nov 8:08 AM ET)
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of November 13, 2026, SRRK stock price climbed to $43.21 with 582,141 million shares trading.
SRRK has a beta of 0.46, meaning it tends to be less sensitive to market movements. SRRK has a correlation of 0.01 to the broad based SPY ETF.
SRRK has a market cap of $5.27 billion. This is considered a Mid Cap stock.
Last quarter Scholar Rock Holding reported $600,000 in Revenue and -$.81 earnings per share. This beat revenue expectation by $321,064 and exceeded earnings estimates by $.04.
In the last 3 years, SRRK traded as high as $61.76 and as low as $6.76.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.
SRRK has outperformed the market in the last year with a return of +43.7%, while the SPY ETF gained +13.4%. However, in the most recent history, SRRK shares have underperformed the stock market with its stock returning -18.6% in the last 3 month period and -1.6% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
SRRK support price is $41.65 and resistance is $44.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK shares will trade within this expected range on the day.
